Portfolio

GenoVision AS
Diagnostics
Norway
www.qiagen.com

GenoVision AS was an innovative biotechnology company with a pioneering technology in nucleic acid sample preparation.

The company focused on systems for automatic isolation and purification of DNA, as well as diagnostic methods used in connection with organ transplants. 

In 2002 GenoVision AS was acquired by Qiagen NV, a company publicly traded on NASDAQ (NASDAQ:QGEN).


Status: Realised

Contact person: Erik Amble



Back to our portfolio

Investment

NeoMed founded GenoVision AS in 1998 and played a major role in all aspects of corporate development.

NeoMed developed the business strategy and formulated the business plan for the company.

NeoMed also facilitated the strategic and transatlantic partnership with Orchid Biosciences, Inc., identified Qiagen N.V. as an acquirer and played a key role in the discussions that led to the acquisition of GenoVision AS.

NeoMed recruited the management team and provided initial financing for the company and built an investor syndicate.

NeoMed sold its shares on NASDAQ in 2003.